BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lau YC, Proietti M, Guiducci E, Blann AD, Lip GY. Atrial Fibrillation and Thromboembolism in Patients With Chronic Kidney Disease. Journal of the American College of Cardiology 2016;68:1452-64. [DOI: 10.1016/j.jacc.2016.06.057] [Cited by in Crossref: 77] [Cited by in F6Publishing: 61] [Article Influence: 12.8] [Reference Citation Analysis]
Number Citing Articles
1 Zou R, Tao J, Shi W, Yang M, Li H, Lin X, Yang S, Hua P. Meta-analysis of safety and efficacy for direct oral anticoagulation treatment of non-valvular atrial fibrillation in relation to renal function. Thromb Res 2017;160:41-50. [PMID: 29096154 DOI: 10.1016/j.thromres.2017.10.013] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
2 Aursulesei V, Costache II. Anticoagulation in chronic kidney disease: from guidelines to clinical practice. Clin Cardiol 2019;42:774-82. [PMID: 31102275 DOI: 10.1002/clc.23196] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 7.3] [Reference Citation Analysis]
3 Hu A, Niu J, Winkelmayer WC. Oral Anticoagulation in Patients With End-Stage Kidney Disease on Dialysis and Atrial Fibrillation. Semin Nephrol 2018;38:618-28. [PMID: 30413255 DOI: 10.1016/j.semnephrol.2018.08.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
4 Proietti R, Gonzini L, Pizzimenti G, Ledda A, Sanna P, AlTurki A, Russo V, Lencioni M; ATA-AF Investigators. Glomerular filtration rate: A prognostic marker in atrial fibrillation-A subanalysis of the AntiThrombotic Agents Atrial Fibrillation. Clin Cardiol 2018;41:1570-7. [PMID: 30144119 DOI: 10.1002/clc.23065] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
5 Carmena R, Ascaso JF, Redon J. Chronic kidney disease as a cardiovascular risk factor. J Hypertens 2020;38:2110-21. [PMID: 32649622 DOI: 10.1097/HJH.0000000000002506] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 Turakhia MP, Blankestijn PJ, Carrero JJ, Clase CM, Deo R, Herzog CA, Kasner SE, Passman RS, Pecoits-Filho R, Reinecke H, Shroff GR, Zareba W, Cheung M, Wheeler DC, Winkelmayer WC, Wanner C; Conference Participants. Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Eur Heart J 2018;39:2314-25. [PMID: 29522134 DOI: 10.1093/eurheartj/ehy060] [Cited by in Crossref: 92] [Cited by in F6Publishing: 75] [Article Influence: 30.7] [Reference Citation Analysis]
7 Chang S, Wu CV, Yeh Y, Kuo C, Chen Y, Wen M, See L, Huang Y. Efficacy and Safety of Oral Anticoagulants in Patients With Atrial Fibrillation and Stages 4 or 5 Chronic Kidney Disease. The American Journal of Medicine 2019;132:1335-1343.e6. [DOI: 10.1016/j.amjmed.2019.06.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
8 Ravera M, Bussalino E, Paoletti E, Bellasi A, Di Lullo L, Fusaro M. Haemorragic and thromboembolic risk in CKD patients with non valvular atrial fibrillation: Do we need a novel risk score calculator? International Journal of Cardiology 2019;274:179-85. [DOI: 10.1016/j.ijcard.2018.07.066] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
9 Fuster V. Editor-in-Chief's Top Picks From 2016: Part Two. J Am Coll Cardiol 2017;69:1010-42. [PMID: 28231931 DOI: 10.1016/j.jacc.2017.01.005] [Reference Citation Analysis]
10 Lip GY, Al-saady N, Ezekowitz MD, Banach M, Goette A. The relationship of renal function to outcome: A post hoc analysis from the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study. American Heart Journal 2017;193:16-22. [DOI: 10.1016/j.ahj.2017.07.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
11 Ronco F, Mazzone P, Hosseinian L, Genovesi S. Recent Advances in Stroke Prevention in Patients with Atrial Fibrillation and End-Stage Renal Disease. Cardiorenal Med 2017;7:207-17. [PMID: 28736561 DOI: 10.1159/000470856] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
12 Potpara TS, Ferro CJ, Lip GYH. Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction. Nat Rev Nephrol 2018;14:337-51. [PMID: 29578207 DOI: 10.1038/nrneph.2018.19] [Cited by in Crossref: 41] [Cited by in F6Publishing: 30] [Article Influence: 10.3] [Reference Citation Analysis]
13 Atarashi H, Uchiyama S, Inoue H, Kitazono T, Yamashita T, Shimizu W, Ikeda T, Kamouchi M, Kaikita K, Fukuda K, Origasa H, Shimokawa H. Ischemic stroke, hemorrhage, and mortality in patients with non-valvular atrial fibrillation and renal dysfunction treated with rivaroxaban: sub-analysis of the EXPAND study. Heart Vessels 2021;36:1410-20. [PMID: 33728513 DOI: 10.1007/s00380-021-01810-5] [Reference Citation Analysis]
14 Deng H, Shantsila A, Xue Y, Bai Y, Guo P, Potpara TS, Zhan X, Fang X, Liao H, Wu S, Lip GY. Renal function and outcomes after catheter ablation of patients with atrial fibrillation: The Guangzhou atrial fibrillation ablation registry. Archives of Cardiovascular Diseases 2019;112:420-9. [DOI: 10.1016/j.acvd.2019.02.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
15 Proietti M, Lane DA, Boriani G, Lip GY. Stroke Prevention, Evaluation of Bleeding Risk, and Anticoagulant Treatment Management in Atrial Fibrillation Contemporary International Guidelines. Canadian Journal of Cardiology 2019;35:619-33. [DOI: 10.1016/j.cjca.2019.02.009] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 10.7] [Reference Citation Analysis]
16 Richard Conti C. Some Thoughts About Warfarin and NOACS. Cardiovascular Innovations and Applications 2017;2:181-2. [DOI: 10.15212/cvia.2016.0049] [Reference Citation Analysis]
17 Voukalis C, Lip GY. Atrial Fibrillation and End Stage Renal Failure in Patients Receiving Dialysis: Balancing the Risks and Benefits of Stroke Prevention. Canadian Journal of Cardiology 2017;33:705-7. [DOI: 10.1016/j.cjca.2017.02.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
18 Kotalczyk A, Mazurek M, Kalarus Z, Potpara TS, Lip GYH. Stroke prevention strategies in high-risk patients with atrial fibrillation. Nat Rev Cardiol 2021;18:276-90. [PMID: 33110242 DOI: 10.1038/s41569-020-00459-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
19 Grosse GM, Schwedhelm E, Worthmann H, Choe CU. Arginine Derivatives in Cerebrovascular Diseases: Mechanisms and Clinical Implications. Int J Mol Sci 2020;21:E1798. [PMID: 32150996 DOI: 10.3390/ijms21051798] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
20 Kumar S, Lim E, Covic A, Verhamme P, Gale CP, Camm AJ, Goldsmith D. Anticoagulation in Concomitant Chronic Kidney Disease and Atrial Fibrillation: JACC Review Topic of the Week. J Am Coll Cardiol 2019;74:2204-15. [PMID: 31648714 DOI: 10.1016/j.jacc.2019.08.1031] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 17.0] [Reference Citation Analysis]
21 Chantrarat T, Krittayaphong R. Oral anticoagulation and cardiovascular outcomes in patients with atrial fibrillation and chronic kidney disease in Asian Population, Data from the COOL-AF Thailand registry. Int J Cardiol 2021;323:90-9. [PMID: 32828960 DOI: 10.1016/j.ijcard.2020.08.068] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Raschi E, Bianchin M, De Ponti R, De Ponti F, Ageno W. Emerging therapeutic uses of direct-acting oral anticoagulants: An evidence-based perspective. Pharmacol Res 2017;120:206-18. [PMID: 28366835 DOI: 10.1016/j.phrs.2017.03.026] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
23 Kloosterman M, Rienstra M, Crijns HJ, Healey JS, Van Gelder IC. The left atrium: An overlooked prognostic tool. Eur J Prev Cardiol 2017;24:389-91. [PMID: 28067538 DOI: 10.1177/2047487316686633] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
24 Zaman JAB, Bhandari AK. Oral Anticoagulants in Patients With Atrial Fibrillation and End-Stage Renal Disease. J Cardiovasc Pharmacol Ther 2019;24:499-508. [PMID: 31284744 DOI: 10.1177/1074248419858116] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
25 Garlo KG, Steele DJR, Nigwekar SU, Chan KE. Demystifying the Benefits and Harms of Anticoagulation for Atrial Fibrillation in Chronic Kidney Disease. Clin J Am Soc Nephrol 2019;14:125-36. [PMID: 30593489 DOI: 10.2215/CJN.06430518] [Cited by in Crossref: 6] [Article Influence: 1.5] [Reference Citation Analysis]
26 Proietti M, Vitolo M, Lip GYH. Integrated care and outcomes in patients with atrial fibrillation and comorbidities. Eur J Clin Invest 2021;51:e13498. [PMID: 33482011 DOI: 10.1111/eci.13498] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
27 Airy M, Schold JD, Jolly SE, Arrigain S, Bansal N, Winkelmayer WC, Nally JV Jr, Navaneethan SD. Cause-Specific Mortality in Patients with Chronic Kidney Disease and Atrial Fibrillation. Am J Nephrol 2018;48:36-45. [PMID: 30048961 DOI: 10.1159/000491023] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
28 Salam AM. Atrial Fibrillation in Middle Eastern Arabs and South Asians: Summary of Published Articles in the Arabian Gulf. Heart Views 2019;20:158-65. [PMID: 31803372 DOI: 10.4103/HEARTVIEWS.HEARTVIEWS_116_19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
29 Khan AA, Lip GYH. Role of chronic kidney disease and atrial fibrillation in outcomes of patients with ischemic stroke. Eur J Neurol 2018;25:1009-10. [PMID: 29682860 DOI: 10.1111/ene.13664] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
30 Kodani E, Atarashi H, Inoue H, Okumura K, Yamashita T, Origasa H; J-RHYTHM Registry Investigators. Impact of creatinine clearance on outcomes in patients with non-valvular atrial fibrillation: a subanalysis of the J-RHYTHM Registry. Eur Heart J Qual Care Clin Outcomes 2018;4:59-68. [PMID: 28950373 DOI: 10.1093/ehjqcco/qcx032] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 6.3] [Reference Citation Analysis]
31 Wanner C, Herzog CA, Turakhia MP, Blankestijn PJ, Carrero J, Clase CM, Deo R, Kasner SE, Passman RS, Pecoits-filho R, Reinecke H, Shroff GR, Zareba W, Cheung M, Wheeler DC, Winkelmayer WC. Chronic kidney disease and arrhythmias: highlights from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International 2018;94:231-4. [DOI: 10.1016/j.kint.2018.05.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
32 Chantrarat T, Hauythan S. The change of renal functions after nonvitamin K oral anticoagulants in patients with atrial fibrillation. Int J Cardiol Heart Vasc 2021;35:100844. [PMID: 34386573 DOI: 10.1016/j.ijcha.2021.100844] [Reference Citation Analysis]
33 Su X, Yan B, Wang L, Lv J, Cheng H, Chen Y. Oral Anticoagulant Agents in Patients With Atrial Fibrillation and CKD: A Systematic Review and Pairwise Network Meta-analysis. Am J Kidney Dis 2021;78:678-689.e1. [PMID: 33872690 DOI: 10.1053/j.ajkd.2021.02.328] [Reference Citation Analysis]
34 Zhang Y, Han Y, Gao P, Mo Y, Hao S, Huang J, Ye F, Li Z, Zheng L, Yao X, Li Z, Li X, Wang X, Huang CJ, Jin B, Zhang Y, Yang G, Alfreds ST, Kanov L, Sylvester KG, Widen E, Li L, Ling X. Electronic Health Record-Based Prediction of 1-Year Risk of Incident Cardiac Dysrhythmia: Prospective Case-Finding Algorithm Development and Validation Study. JMIR Med Inform 2021;9:e23606. [PMID: 33595452 DOI: 10.2196/23606] [Reference Citation Analysis]
35 Tapoi L, Ureche C, Sascau R, Badarau S, Covic A. Atrial fibrillation and chronic kidney disease conundrum: an update. J Nephrol 2019;32:909-17. [DOI: 10.1007/s40620-019-00630-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
36 Cases A, Gomez P, Broseta JJ, Perez Bernat E, Arjona Barrionuevo JD, Portolés JM, Gorriz JL. Non-valvular Atrial Fibrillation in CKD: Role of Vitamin K Antagonists and Direct Oral Anticoagulants. A Narrative Review. Front Med (Lausanne) 2021;8:654620. [PMID: 34604247 DOI: 10.3389/fmed.2021.654620] [Reference Citation Analysis]
37 Lip GY, Freedman B, De Caterina R, Potpara TS. Stroke prevention in atrial fibrillation: Past, present and future: Comparing the guidelines and practical decision-making. Thromb Haemost 2017;117:1230-9. [DOI: 10.1160/th16-11-0876] [Cited by in Crossref: 244] [Cited by in F6Publishing: 61] [Article Influence: 48.8] [Reference Citation Analysis]
38 Li L, Selvin E, Hoogeveen RC, Soliman EZ, Chen LY, Norby FL, Alonso A. 6-year change in high sensitivity cardiac troponin T and the risk of atrial fibrillation in the Atherosclerosis Risk in Communities cohort. Clin Cardiol 2021;44:1594-601. [PMID: 34545585 DOI: 10.1002/clc.23727] [Reference Citation Analysis]
39 Kimachi M, Furukawa TA, Kimachi K, Goto Y, Fukuma S, Fukuhara S. Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease. Cochrane Database Syst Rev 2017;11:CD011373. [PMID: 29105079 DOI: 10.1002/14651858.CD011373.pub2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 25] [Article Influence: 3.2] [Reference Citation Analysis]
40 Kodani E, Akao M. Atrial fibrillation and stroke prevention: state of the art-epidemiology and pathophysiology: new risk factors, concepts and controversies. Eur Heart J Suppl 2020;22:O1-O13. [PMID: 33380940 DOI: 10.1093/eurheartj/suaa176] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Yamagami F, Tajiri K, Yumino D, Ieda M. Uremic Toxins and Atrial Fibrillation: Mechanisms and Therapeutic Implications. Toxins (Basel) 2019;11:E597. [PMID: 31614923 DOI: 10.3390/toxins11100597] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
42 Zou H, Li Y, Xu G. Management of anticoagulation and antiplatelet therapy in patients with primary membranous nephropathy. BMC Nephrol 2019;20:442. [PMID: 31791286 DOI: 10.1186/s12882-019-1637-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
43 Kotalczyk A, Ding WY, Wong CF, Rao A, Gupta D, Lip GYH. Atrial Fibrillation in Patients with Chronic Kidney Disease. Cardiol Clin 2021;39:435-46. [PMID: 34247756 DOI: 10.1016/j.ccl.2021.04.005] [Reference Citation Analysis]
44 Ding WY, Harrison S, Gupta D, Lip GYH, Lane DA. Stroke and Bleeding Risk Assessments in Patients With Atrial Fibrillation: Concepts and Controversies. Front Med (Lausanne) 2020;7:54. [PMID: 32154260 DOI: 10.3389/fmed.2020.00054] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
45 Benn M. Atrial Fibrillation and Chronic Kidney Disease. Eur Heart J 2021;42:2824-6. [PMID: 34023873 DOI: 10.1093/eurheartj/ehab301] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Meng Y, Wang S, Liu P, Zhang Y, Tang B, Zhu C, Wang S, Yang Q, Lu T, Nie C. The preoperative glomerular filtration rate predicts new-onset postoperative atrial fibrillation in patients with hypertrophic obstructive cardiomyopathy who undergo isolated septal myectomy. J Thorac Dis 2021;13:1612-23. [PMID: 33841953 DOI: 10.21037/jtd-20-3164] [Reference Citation Analysis]
47 Ding WY, Gupta D, Wong CF, Lip GYH. Pathophysiology of atrial fibrillation and chronic kidney disease. Cardiovasc Res 2021;117:1046-59. [PMID: 32871005 DOI: 10.1093/cvr/cvaa258] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
48 Singh SM, Abdel-Qadir H, Pang A, Fang J, Koh M, Dorian P, Wijeysundera HC, Ko DT. Population Trends in All-Cause Mortality and Cause Specific-Death With Incident Atrial Fibrillation. J Am Heart Assoc 2020;9:e016810. [PMID: 32924719 DOI: 10.1161/JAHA.120.016810] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
49 Davis E, Darais D, Fuji K, Nekola P, Bashir K. Prescribing and Safety of Direct-Acting Oral Anticoagulants Compared to Warfarin in Patients with Atrial Fibrillation on Chronic Hemodialysis. Pharmacy (Basel) 2020;8:E37. [PMID: 32164234 DOI: 10.3390/pharmacy8010037] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
50 Glikson M, Wolff R, Hindricks G, Mandrola J, Camm AJ, Lip GYH, Fauchier L, Betts TR, Lewalter T, Saw J, Tzikas A, Sternik L, Nietlispach F, Berti S, Sievert H, Bertog S, Meier B, Lenarczyk R, Nielsen-kudsk JE, Tilz R, Kalarus Z, Boveda S, Deneke T, Heinzel FR, Landmesser U, Hildick-smith D; ESC Scientific Document Group. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion – an update. EP Europace 2020;22:184-184. [DOI: 10.1093/europace/euz258] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 12.0] [Reference Citation Analysis]
51 Proietti M, Airaksinen KEJ, Rubboli A, Schlitt A, Kiviniemi T, Karjalainen PP, Lip GYH; AFCAS Study Group. Synergic impact of oral anticoagulation control and renal function in determining major adverse events in atrial fibrillation patients undergoing percutaneous coronary intervention: insights from the AFCAS registry. Clin Res Cardiol 2017;106:420-7. [PMID: 28078448 DOI: 10.1007/s00392-016-1071-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
52 Ahuja KR, Ariss RW, Nazir S, Vyas R, Saad AM, Macciocca M, Moukarbel GV. The Association of Chronic Kidney Disease With Outcomes Following Percutaneous Left Atrial Appendage Closure. JACC Cardiovasc Interv 2021;14:1830-9. [PMID: 34412801 DOI: 10.1016/j.jcin.2021.06.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Lee SR, Choi EK, Han KD, Jung JH, Cha MJ, Oh S, Lip GYH. Non-Vitamin K Antagonist Oral Anticoagulants in Asian Patients With Supranormal Renal Function. Stroke 2019;50:1480-9. [PMID: 31084339 DOI: 10.1161/STROKEAHA.118.024264] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
54 Stefil M, Nabrdalik K, Lip GY. Renal Disease and Atrial Fibrillation. Cardiac Electrophysiology Clinics 2021;13:95-112. [DOI: 10.1016/j.ccep.2020.11.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Brandes A, Smit MD, Nguyen BO, Rienstra M, Van Gelder IC. Risk Factor Management in Atrial Fibrillation. Arrhythm Electrophysiol Rev 2018;7:118-27. [PMID: 29967684 DOI: 10.15420/aer.2018.18.2] [Cited by in Crossref: 47] [Cited by in F6Publishing: 31] [Article Influence: 11.8] [Reference Citation Analysis]
56 Bertini M, Vitali F, Santini L, Tavoletta V, Giano A, Savarese G, Dello Russo A, Santobuono VE, Mattera A, Lavalle C, Amellone C, Pecora D, Calvanese R, Rapacciuolo A, Campari M, Valsecchi S, Calò L. Implantable defibrillator-detected heart failure status predicts atrial fibrillation occurrence. Heart Rhythm 2022. [DOI: 10.1016/j.hrthm.2022.01.020] [Reference Citation Analysis]
57 Lee WC, Wu PJ, Fang CY, Chen HC, Chen MC. Impact of chronic kidney disease on atrial fibrillation recurrence following radiofrequency and cryoballoon ablation: A meta-analysis. Int J Clin Pract 2021;:e14173. [PMID: 33756030 DOI: 10.1111/ijcp.14173] [Reference Citation Analysis]
58 Altawalbeh SM, Alshogran OY, Smith KJ. Cost-Utility Analysis of Apixaban versus Warfarin in Atrial Fibrillation Patients with Chronic Kidney Disease. Value Health 2018;21:1365-72. [PMID: 30502779 DOI: 10.1016/j.jval.2018.06.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
59 Yamagami F, Tajiri K, Doki K, Hattori M, Honda J, Aita S, Harunari T, Yamasaki H, Murakoshi N, Sekiguchi Y, Homma M, Takahashi N, Aonuma K, Nogami A, Ieda M. Indoxyl Sulphate is Associated with Atrial Fibrillation Recurrence after Catheter Ablation. Sci Rep 2018;8:17276. [PMID: 30467393 DOI: 10.1038/s41598-018-35226-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
60 Chiang CE, Okumura K, Zhang S, Chao TF, Siu CW, Wei Lim T, Saxena A, Takahashi Y, Siong Teo W. 2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation. J Arrhythm 2017;33:345-67. [PMID: 28765771 DOI: 10.1016/j.joa.2017.05.004] [Cited by in Crossref: 80] [Cited by in F6Publishing: 63] [Article Influence: 16.0] [Reference Citation Analysis]
61 Kodani E, Inoue H, Atarashi H, Tomita H, Okumura K, Yamashita T, Origasa H; J-RHYTHM Registry Investigators. Predictive ability of creatinine clearance versus estimated glomerular filtration rate for outcomes in patients with non-valvular atrial fibrillation: Subanalysis of the J-RHYTHM Registry. Int J Cardiol Heart Vasc 2020;29:100559. [PMID: 32566722 DOI: 10.1016/j.ijcha.2020.100559] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
62 Sabbag A, Yao X, Siontis KC, Noseworthy PA. Anticoagulation for Stroke Prevention in Older Adults with Atrial Fibrillation and Comorbidity: Current Evidence and Treatment Challenges. Korean Circ J 2018;48:873-89. [PMID: 30238705 DOI: 10.4070/kcj.2018.0261] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
63 Xiao L, Ma M, Gu M, Han Y, Wang H, Zi W, Yang D, Hao Y, Lv Q, Ye R, Sun W, Zhu W, Xu G, Liu X; ACTUAL Investigators. Renal impairment on clinical outcomes following endovascular recanalization. Neurology 2020;94:e464-73. [PMID: 31857435 DOI: 10.1212/WNL.0000000000008748] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
64 Brophy DF. Apixaban Dosing in Chronic Kidney Disease. Journal of the American College of Cardiology 2017;69:1211. [DOI: 10.1016/j.jacc.2016.11.074] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
65 Reinecke H, Jürgensmeyer S, Engelbertz C, Gerss J, Kirchhof P, Breithardt G, Bauersachs R, Wanner C. Design and rationale of a randomised controlled trial comparing apixaban to phenprocoumon in patients with atrial fibrillation on chronic haemodialysis: the AXADIA-AFNET 8 study. BMJ Open 2018;8:e022690. [PMID: 30206088 DOI: 10.1136/bmjopen-2018-022690] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
66 Lip GY, Banerjee A, Boriani G, Chiang CE, Fargo R, Freedman B, Lane DA, Ruff CT, Turakhia M, Werring D, Patel S, Moores L. Antithrombotic Therapy for Atrial Fibrillation. Chest 2018;154:1121-201. [DOI: 10.1016/j.chest.2018.07.040] [Cited by in Crossref: 397] [Cited by in F6Publishing: 344] [Article Influence: 99.3] [Reference Citation Analysis]